ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Metformin and CI-AKI Risk in STEMI: Evaluation Using Propensity Score Weighting Method [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2022; 50(6): 422-430 | DOI: 10.5543/tkda.2022.22430

Metformin and CI-AKI Risk in STEMI: Evaluation Using Propensity Score Weighting Method

Sedat Kalkan1, Ali Karagöz1, Süleyman Çağan Efe1, Mustafa Azmi Sungur2, Barış Şimşek2, Mehmet Fatih Yılmaz2, Ulaankhuu Batgerel3, Fatih Yılmaz1, Ibrahim Halil Tanboğa4, Vecih Oduncu5, Can Yücel Karabay2, Cevat Kırma1
1Department of Cardiology, Koşuyolu Kartal Heart Training and Research Hospital, İstanbul, Turkey
2Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey
3Department of Cardiology, Acıbadem Kadıköy Hospital, İstanbul, Turkey
4Department of Cardiology, Hisar Intercontinental Hospital, İstanbul, Turkey
5Department of Cardiology, Bahçeşehir University Hospital, İstanbul, Turkey


OBJECTIVE
Discontinuation of metformin therapy is a frequent clinical practice to reduce the risk of contrast-induced acute kidney injury (CI-AKI) in diabetic ST-segment elevation myocardial
infarction patients using metformin. There is insufficient evidence in the literature to support this approach. The aim of this study is to determine whether the risk of contrastinduced
acute kidney injury is different in diabetic ST-segment elevation myocardial infarction patients using metformin compared to those not taking metformin.


METHODS
The study population consisted of patients with ST-segment elevation myocardial infarction admitted to the centers that participated in this study between 2014 and 2019 and
underwent primary percutaneous intervention. Diabetic patients (n = 343) that met the study inclusion criteria were divided into 2 groups as who have been receiving metformin and who
have not. Patients’ creatinine values on admission and peak creatinine values were compared in order to determine whether they have developed contrast-induced acute kidney injury. The
2 groups were compared using conditional logistic regression analysis conducted with the inverse probability weighting method.


RESULTS
Non-weighted classic multivariable logistic regression analysis revealed that metformin use was not associated with acute kidney injury. Weighted conditional multivariable logistic
regression revealed that the increase in the risk of acute kidney injury was associated with baseline creatinine levels [odds ratio: 1.49 (1.06-2.10; 95% CI) P =.02] and that the increase
in the risk of contrast-induced acute kidney injury was not associated with metformin usage [odds ratio: 0.92 (0.57-1.50, 95% CI) P =.74].


CONCLUSION
No statistically significant difference was found between the metformin and nonmetformin users among the diabetic ST-segment elevation myocardial infarction patients who underwent primary percutaneous intervention in the risk of contrast-induced acute kidney injury.

Keywords: Contrast nephropathy, contrast-induced acute kidney injury, metformin, ST-segment elevation myocardial infarction

How to cite this article
Sedat Kalkan, Ali Karagöz, Süleyman Çağan Efe, Mustafa Azmi Sungur, Barış Şimşek, Mehmet Fatih Yılmaz, Ulaankhuu Batgerel, Fatih Yılmaz, Ibrahim Halil Tanboğa, Vecih Oduncu, Can Yücel Karabay, Cevat Kırma. Metformin and CI-AKI Risk in STEMI: Evaluation Using Propensity Score Weighting Method. Turk Kardiyol Dern Ars. 2022; 50(6): 422-430

Corresponding Author: Sedat Kalkan, Türkiye
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.